BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 15915463)

  • 21. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.
    Santantonio T; Fasano M; Durantel S; Barraud L; Heichen M; Guastadisegni A; Pastore G; Zoulim F
    Antivir Ther; 2009; 14(4):557-65. PubMed ID: 19578241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
    Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
    Suzuki F; Kumada H; Nakamura H
    J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.
    Akman SA; Kose S; Halicioglu O
    Int J Infect Dis; 2010 Mar; 14(3):e236-9. PubMed ID: 19665408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
    Karatayli E; Karayalçin S; Karaaslan H; Kayhan H; Türkyilmaz AR; Sahin F; Yurdaydin C; Bozdayi AM
    Antivir Ther; 2007; 12(5):761-8. PubMed ID: 17713159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.
    Liu LJ; Wang JH; Du SC; Tian JH; Yang RF; Wei L
    J Viral Hepat; 2010 Mar; 17 Suppl 1():66-72. PubMed ID: 20586936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
    Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
    J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus.
    Zhang Y; Zhang Y; Kang Y; Wang J; Liu H; Zhu H; Qin Y; Mao R; Lin X; Lu M; Zhang J
    J Virol Methods; 2014 Jun; 201():51-6. PubMed ID: 24583110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.
    van Bömmel F; Trojan J; Deterding K; Wedemeyer H; Wasmuth HE; Hüppe D; Möller B; Bock FJ; Feucht HH; Berg T
    Antivir Ther; 2012; 17(6):1049-58. PubMed ID: 22892524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.
    Villeneuve JP; Durantel D; Durantel S; Westland C; Xiong S; Brosgart CL; Gibbs CS; Parvaz P; Werle B; Trépo C; Zoulim F
    J Hepatol; 2003 Dec; 39(6):1085-9. PubMed ID: 14642631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
    Tacke F; Gehrke C; Luedde T; Heim A; Manns MP; Trautwein C
    J Virol; 2004 Aug; 78(16):8524-35. PubMed ID: 15280461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
    Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
    Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
    J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
    Rodriguez-Frias F; Jardi R; Schaper M; Gimferrer M; Elefsiniotis I; Tabernero D; Esteban R; Buti M
    J Med Virol; 2007 Nov; 79(11):1671-3. PubMed ID: 17854030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
    Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
    J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.
    Svicher V; Alteri C; Gori C; Salpini R; Marcuccilli F; Bertoli A; Longo R; Bernassola M; Gallinaro V; Romano S; Visca M; Ursitti A; Feasi M; Micheli V; Angelico M; Cassola G; Parruti G; Gubertini G; De Sanctis GM; Ceccherini-Silberstein F; Cappiello G; Spanò A; Perno CF
    Dig Liver Dis; 2010 Dec; 42(12):902-7. PubMed ID: 20621632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The replication capacity and drug sensitivity of Adefovir dipivoxil-resistant HBV mutants in vivo].
    Lei J; Gao Z; Xu L; Liu L; Tang H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2011 Feb; 28(1):125-8. PubMed ID: 21485198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.